**Name of journal:** *World Journal of Meta-Analysis*

**Manuscript NO:** 47862

**Manuscript Type:** EDITORIAL

**Gastrointestinal stress ulcer prophylaxis in the intensive care unit, where is the data?**

Alshami A *et al*. Stress ulcer prophylaxis

Abbas Alshami, Sheily Vianney Barona, Joseph Varon, Salim Surani

**Abbas Alshami, Sheily Vianney Barona,** Dorrington Medical Associates, Houston, TX 77030, United States

**Abbas Alshami,** University of Baghdad College of Medicine, Baghdad 12114, Iraq

**Sheily Vianney Barona,** Benemerita Universidad Autonoma de Puebla, Puebla 72000, Mexico

**Joseph Varon,** United General Hospital, Sedro Woolley, WA 98284, United States

**Joseph Varon,** Critical Care Services, United Memorial Medical Center, Houston, TX 77091, United States

**Joseph Varon,** Acute and Continuing Care, University of Texas Health Science Center at Houston, Houston, TX 77030, United States

**Joseph Varon,** Medicine, University of Texas Medical Branch at Galveston Houston, Galveston, TX 77555, United States

**Salim Surani,** Department of Pulmonary, Critical Care and Sleep Medicine, Texas A&M University, Health Science Center, Bryan, TX 77807, United States

**Salim Surani,** Pulmonary and Critical Care Fellowship Program, Bay Area Medical Center, Marinette, WI 54143, United States

**Salim Surani,** Medical Critical Care Services, Christus Spohn Hospitals-Corpus Christi, Corpus Christi, TX 78404, United States

**ORCID number:** Abbas Alshami (0000-0003-0726-3498); Sheily Vianney Barona Hernandez (0000-0002-4672-5133); Joseph Varon (0000-0002-7622-9974); Salim Surani (0000-0001-7105-4266).

**Author contributions**: All authors have contributed to the preparation of the manuscript, search and review of the editorial.

**Conflict-of-interest statement**: None of the authors have any conflict of interest to disclose.

**Open-Access**: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Corresponding author**: **Salim Surani, MD, MPH, MSHM, FACP, FCCP, FAASM,** **Professor,** Medical Critical Care Services, Christus Spohn Hospitals-Corpus Christi, 701 Ayers St, Corpus Christi, TX 78404, United States. srsurani@hotmail.com

**Telephone**: +1-361- 8857722

**Received:** January 25, 2019

**Peer-review started**: January 25, 2019

**First decision**: February 21, 2019

**Revised:** March 27, 2019

**Accepted:** March 27, 2019

**Article in press**:

**Published online:**

**Abstract**

Stress-induced gastrointestinal ulcers are common among patients admitted to the intensive care unit (ICU). These ulcers impose significant morbidity and mortality, therefore, stress ulcer prophylaxis (SUP) is a common clinical practice among healthcare providers dealing with these critically-ill patients. Several strategies for SUP have been suggested over the past four decades, with acid suppressive therapies being the most commonly used in the ICU. Whether SUP is effective and safe, or not, remains a topic of controversy. The data is still conflicting, and provision of a simple answer is not feasible at the present time. Recently, a large phase IV, multicenter, randomized clinical trial (SUP-ICU), negated the benefits (and harms) of proton pump inhibitors as SUP. This article reviews some of these controversies.

**Key words:** Gastrointestinal stress ulcers; Proton pump inhibitors; H2-antagonists; Prophylaxis; Complications

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tips**: Stress ulcer prophylaxis (SUP) is a prevalent clinical practice in patients admitted to intensive care unit (ICU). However, there is no high-quality evidence to support its use. Indeed, current data on its efficacy and complications remains conflictive at best, and until an explicit evidence becomes available, health care providers working in the ICU must carefully analyze the advantages and disadvantages of SUP based on each patient’s presentation and comorbidities.

Alshami A, Barona SV, Varon J, Surani S. Gastrointestinal stress ulcer prophylaxis in the intensive care unit, where is the data? *World J Meta-Anal* 2019; In press

**GASTROINTESTINAL STRESS ULCER PROPHYLAXIS IN THE INTENSIVE CARE UNIT, WHERE IS THE DATA?**

Patients with major illnesses (*i.e.*, trauma, shock, sepsis, head injury) are at risk of developing a variety of erosions or erosive lesions in the mucosa of the gastroduodenal tract (known as stress ulcers)[1]. These erosions are usually acute, multiple, superficial, and occur mainly in the fundus and body of the stomach, which makes them present as a distinct clinicopathological entity different from other types of ulcers (*i.e.*, reactivation of chronic peptic ulcers, Cushing’s ulcers due to head trauma, or drug-induced gastritis).[1] Endoscopic evaluation has revealed that more than 75% of critically ill patients develop gross gastric lesions within 72 h of admission to the intensive care unit (ICU), and almost 100% of them among extremely critical patients[2]. However, only a minority of these ulcerations bleed. Indeed, overt bleeding (manifested as bloody nasogastric aspirate, hematemesis, or melena), is reported in 20% of patients without stress ulcer prophylaxis (SUP), while < 5% develop clinically significant bleeding (CSB), defined as overt bleeding with transfusion, hemodynamic instability, and/or the need for intervention[2]. These lesions usually remain superficial, and cause sub-epithelial hemorrhages[3]. The occurrence of significant bleeding usually indicates a breach of the submucosa and the development of a true ulcer, and it is associated with increased mortality (*RR* = 2.9, 95%CI = 1.6–5.5), and significant morbidity (increased ICU stay of 6.2 d, 95%CI = 1.0–11.4 d)[4].

It is well known that the most important factor in any gastric ulcer formation is the disruption of balance between gastric acid and gastric wall protective mechanisms, and stress ulcers are no exception. In critically ill patients, activation of sympathetic nervous system, increased catecholamine release and vasoconstriction, hypovolemia, decreased cardiac output, and release of proinflammatory cytokines result in splanchnic hypoperfusion[5]. Subsequently, this hypoperfusion leads to a number of deleterious effects including, ischemic damage to the gastric wall integrity, bicarbonate secretion, gastric hypomotility resulting in delayed emptying of acid, delayed mucosal healing, and reperfusion injury after restoration of splanchnic circulation[5]. In addition, these effects make the gastric wall vulnerable to damage and ulceration by acid, even if it is within a “normal” pH range.

The compelling morbidity and mortality of gastric ulcers have entailed a prompt action to prevent them among critically ill patients. Acid suppressive therapies seemed to be reasonable options after showing efficacy in decreasing the rate of overt and clinically important bleeding[6,7]. They rapidly became a standard critical care practice. A survey of 58 ICUs in North America, mainly in university teaching hospitals, revealed that 84% of patients admitted to the ICUs received SUP, with proton pump inhibitors being the most commonly used agents[8]. It also seems that different proton pump inhibitors (PPIs) have similar efficacies in this clinical setting. Messori *et al*[9] conducted a meta-analysis and equivalence testing to assess the difference between intravenous omeprazole and pantoprazole, and they found that these two agents are equivalent according to reasonable equivalence margins. Moreover, several studies have shown that oral and intravenous routes of PPIs administration showed comparable efficacies in suppressing gastric acid secretion[10-12].

However, later clinical evidence had shown that this therapeutic and prophylactic intervention failed to improve the overall clinical outcomes, and a wide debate has started. Ben-Menachem *et al*[13]found that SUP with histamine receptor 2 (H2) antagonists neither improved all-cause mortality nor reduced length of stay in ICU patients, when compared to placebo or no intervention. Likewise, Kantorova *et al*[14] studied the effect of proton pump inhibitors and H2 antagonists as SUP therapies and found no statistically significant difference in length of ICU stay or mortality. Moreover, the routine use of acid suppressive therapies not only might not improve clinical outcomes, but rather has been reported to cause a variety of potential effects. Gastric acid, in addition to its role in digestion, serves as an important sterilizer of the stomach, and its suppression leads to bacterial and fungal overgrowth and predisposes to nosocomial infections[15]. A large prospective study enrolling 63878 in-hospital non-ventilated patients found that acid suppressive therapies were associated with a 30% increase in hospital acquired pneumonia[16]. Similarly, several clinical studies have found that acid suppressive therapies are associated with increased risk of *Clostridioides difficile* (*C. difficile*) diarrhea Leonard *et al*[17] in a meta-analysis evaluating 2948 patients, revealed a statistically significant association between both PPI and H2 antagonists use and hospital-acquired *C. difficile* infection (OR 1.95, 95%CI: 1.48–2.58). However, this association with *C. difficile* was not established in a larger meta-analysis that enrolled 70862 patients with sepsis, and found no statistically significant correlation between *C. difficile* infection and SUP[18]. This conclusion can be reasonable, especially as *C. difficile* spores, are acid resistant and remain viable at gastric pH[19]. In addition, the cost of treatment should be considered as well. In one study, the use of acid suppressive therapy in ICU patients showed a cost of 8026 US Dollars per patient[20]. Given the number of ICU admissions in the United States alone (5.6 million ICU admissions in 2011), this constitutes an unnecessary heavy economic burden, had this preventive measure been inefficacious[21].

A recent multi-center phase IV randomized clinical trial (SUP-ICU) that involved 3298 patients in multiple European countries revealed that intravenous pantoprazole-receiving patients in the ICU were similar to the placebo group in 90-d mortality, rate of *C. Difficile* infection, rate of pneumonia, and surprisingly even in rate of CSB[22]. However, the study had several limitations, such as clinical (rather than endoscopic) diagnosis of stress ulcer, limited power to detect differences in the subgroup analyses, and more importantly, the study was powered to detect an absolute mortality reduction of 5%, which is quite high and generally implausible in critical patients[23]. Moreover, the incidence of clinically important bleeding in critically ill patients has been reported to be as low as 2.6% in a large multicenter prospective study, further confirming that absolute reduction of mortality of 5% is unreasonable[24].

The large number of conflicting studies make it difficult to draw a simple conclusion regarding the effectiveness of this preventive therapy; therefore, systematic reviews would be suitable means to provide the answer. Several systematic reviews have been conducted. A recent Cochrane systematic review and meta-analysis that included 129 clinical studies, found that SUP interventions, compared to placebo or no intervention, in general decreased the rate of clinically important bleeding, but did not have any effect in the risk of nosocomial pneumonia, all-cause mortality, length of ICU stay, or length of intubation[25]. It also concluded that PPIs were superior to H2 antagonists by decreasing CSB.

Another systematic review and network meta-analysis by Alhazzani *et al*[26] showed that PPIs are the most effective agents to decrease CSB, followed by H2 antagonists. However, they found that neither PPIs nor H2 antagonists did improve the all-cause mortality or the risk of pneumonia compared to placebo or no prophylaxis[26]. Furthermore, a very recent systematic review with meta-analysis and trial sequential analysis (TSA) included 41 trials (included the previously described SUP-ICU) further confirmed previous results, that SUP decreases GI bleeding (overt and clinically important) but not all-cause mortality. However, TSA showed that the evidence of reduction of overt GI bleeding (but not clinically important) was firm. In addition, TSA showed that the required information size to assess the risks of pneumonia and C. difficile enteritis had not been reached, therefore, establishing relations is not plausible yet.

Other options have also been sought to prevent stress ulcers. To avoid disrupting the protective mechanism of the acid, ulcer-protective agents without altering gastric pH have been suggested as SUP. Sucralfate, for example, binds to gastric ulcers and erosions and protects them from damaging effects of gastric acid. López-Herce *et al*[27] found that sucralfate had similar effect to H2 antagonists in decreasing the rate of clinically important bleeding in pediatric patients admitted to ICU (*P* < 0.01), when compared to placebo. However, this option didn’t hold up enough. Another clinical study, comparing sucralfate to no intervention in patients with head trauma, did not show any statistical difference in risk of gastrointestinal bleeding[28]. Moreover, Alhazzani *et al*[26] in their meta-analysis, among other studies, found that sucralfate did not improve the rate of clinically important bleeding when compared to placebo.

Although current level of evidence strongly suggests no improvement in all-cause mortality from SUP, some authors argued that cause-specific mortality reduction, rather than all-cause mortality reduction, should be considered when investigating preventive therapies[29]. Indeed, had all-cause (rather than cause-specific) mortality used as a measure to determine the efficacy of radiotherapy in the management of breast cancer (a valuable intervention with substantial improvement in overall survival), this intervention might never have been introduced, because initial all-cause mortality reduction was insignificant due equivalent deaths from cardiovascular complications of therapy, that were later abolished with subsequent modifications to radio beam which ensured less exposure of the heart and the major vessels to radiation[29]. Meanwhile, recent evidence-based improvements in critical care practice, such as optimal fluid resuscitation (improving splanchnic hypoperfusion) and early provision of enteral feeding, have led to a substantial decrease in rate of CSB, and questions the efficacy of SUP to further decrease the risk of GI bleeding. In a systematic review, Huang and associates analyzed if SUP provided any protections to patients receiving enteral feeding and found no statistically significant difference in rate of gastrointestinal bleeding, mortality, *C. difficile* infection, length of ICU stay, and duration of mechanical ventilation[30]. Therefore, we believe that a large scale clinical trial comparing cause-specific mortality and morbidity between a group with early enteral feeding plus SUP to controls with early enteral feeding alone will adequately address this clinical issue. In a nutshell, the current data is neither satisfactory to prove the efficacy of this preventive measure nor to deny it, and until further evidence becomes available, it is at the discretion of the healthcare provider whether to administer SUP to critical patients.

**REFRENCES**

1 **Moody FG**, Cheung LY. Stress ulcers: their pathogenesis, diagnosis, and treatment. *Surg Clin North Am* 1976; **56**: 1469-1478 [PMID: 793064 DOI: 10.1016/S0039-6109(16)41099-6]

2 **Laine L**, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. *Gastroenterology* 2008; **135**: 41-60 [PMID: 18549814 DOI: 10.1053/j.gastro.2008.05.030]

3 **Bardou M**, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. *Nat Rev Gastroenterol Hepatol* 2015; **12**: 98-107 [PMID: 25560847 DOI: 10.1038/nrgastro.2014.235]

4 **Cook DJ**, Griffith LE, Walter SD, Guyatt GH, Meade MO, Heyland DK, Kirby A, Tryba M; Canadian Critical Care Trials Group. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. *Crit Care* 2001; **5**: 368-375 [PMID: 11737927 DOI: 10.1186/cc1071]

5 **Quenot JP**, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? *Curr Opin Crit Care* 2009; **15**: 139-143 [PMID: 19578324 DOI: 10.1097/MCC.0b013e32832978e0]

6 **Cook DJ**, Witt LG, Cook RJ, Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. *Am J Med* 1991; **91**: 519-527 [PMID: 1835294 DOI: 10.1016/0002-9343(91)90189-5]

7 **Cook DJ**, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. *JAMA* 1996; **275**: 308-314 [PMID: 8544272 DOI: 10.1001/jama.1996.03530280060038]

8 **Barletta JF**, Kanji S, MacLaren R, Lat I, Erstad BL; American-Canadian consortium for Intensive care Drug utilization (ACID) Investigators. Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. *J Crit Care* 2014; **29**: 955-960 [PMID: 25081626 DOI: 10.1016/j.jcrc.2014.06.025]

9 **Messori A**, Fadda V, Maratea D, Gatto R, Trippoli S, De Rosa M, Marinai C. Intravenous proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: determining statistical equivalence according to evidence-based methods. *Int J Clin Pharmacol Ther* 2014; **52**: 825-829 [PMID: 25074869 DOI: 10.5414/CP202124]

10 **Tsoi KK**, Hirai HW, Sung JJ. Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. *Aliment Pharmacol Ther* 2013; **38**: 721-728 [PMID: 23915096 DOI: 10.1111/apt.12441]

11 **Neumann I**, Letelier LM, Rada G, Claro JC, Martin J, Howden CW, Yuan Y, Leontiadis GI. Comparison of different regimens of proton pump inhibitors for acute peptic ulcer bleeding. *Cochrane Database Syst Rev* 2013; CD007999 [PMID: 23760821 DOI: 10.1002/14651858.CD007999.pub2]

12 **Tringali A**, Manta R, Sica M, Bassotti G, Marmo R, Mutignani M. Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis. *Br J Clin Pharmacol* 2017; **83**: 1619-1635 [PMID: 28181291 DOI: 10.1111/bcp.13258]

13 **Ben-Menachem T**, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, Divine G, Verter J, Bresalier RS. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. *Ann Intern Med* 1994; **121**: 568-575 [PMID: 8085688 DOI: 10.7326/0003-4819-121-8-199410150-00003]

14 **Kantorova I**, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, Ochmann J. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. *Hepatogastroenterology* 2004; **51**: 757-761 [PMID: 15143910]

15 **Thorens J**, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, Gonvers JJ, Fried M. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. *Gut* 1996; **39**: 54-59 [PMID: 8881809 DOI: 10.1136/gut.39.1.54]

16 **Herzig SJ**, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. *JAMA* 2009; **301**: 2120-2128 [PMID: 19470989 DOI: 10.1001/jama.2009.722]

17 **Leonard J**, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007; **102**: 2047-56; quiz 2057 [PMID: 17509031 DOI: 10.1111/j.1572-0241.2007.01275.x]

18 **Sasabuchi Y**, Matsui H, Lefor AK, Fushimi K, Yasunaga H. Risks and Benefits of Stress Ulcer Prophylaxis for Patients With Severe Sepsis. *Crit Care Med* 2016; **44**: e464-e469 [PMID: 27002276 DOI: 10.1097/CCM.0000000000001667]

19 **Leffler DA**, Lamont JT. Clostridium difficile infection. *N Engl J Med* 2015; **372**: 1539-1548 [PMID: 25875259 DOI: 10.1056/NEJMra1403772]

20 **Nachnani JS**, Bulchandani D, Moormeier J, Foxworth J. Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients. *J Hosp Med* 2009; **4**: E10-E14 [PMID: 19827047 DOI: 10.1002/jhm.492]

21 **Barrett** **ML**, Smith MW, Elixhauser A, Honigman LS, Pines J. Utilization of Intensive Care Services, 2011: Statistical Brief #185. Healthcare Cost and Utilization Project Statistical Briefs. Rockville: Agency for Healthcare Research and Quality, 2014

22 **Krag M**, Marker S, Perner A, Wetterslev J, Wise MP, Schefold JC, Keus F, Guttormsen AB, Bendel S, Borthwick M, Lange T, Rasmussen BS, Siegemund M, Bundgaard H, Elkmann T, Jensen JV, Nielsen RD, Liboriussen L, Bestle MH, Elkjær JM, Palmqvist DF, Bäcklund M, Laake JH, Bådstøløkken PM, Grönlund J, Breum O, Walli A, Winding R, Iversen S, Jarnvig IL, White JO, Brand B, Madsen MB, Quist L, Thornberg KJ, Møller A, Wiis J, Granholm A, Anthon CT, Meyhoff TS, Hjortrup PB, Aagaard SR, Andreasen JB, Sørensen CA, Haure P, Hauge J, Hollinger A, Scheuzger J, Tuchscherer D, Vuilliomenet T, Takala J, Jakob SM, Vang ML, Pælestik KB, Andersen KLD, van der Horst ICC, Dieperink W, Fjølner J, Kjer CKW, Sølling C, Sølling CG, Karttunen J, Morgan MPG, Sjøbø B, Engstrøm J, Agerholm-Larsen B, Møller MH; SUP-ICU trial group. Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU. *N Engl J Med* 2018; **379**: 2199-2208 [PMID: 30354950 DOI: 10.1056/NEJMoa1714919]

23 **Ridgeon EE**, Bellomo R, Aberegg SK, Sweeney RM, Varughese RS, Landoni G, Young PJ. Effect sizes in ongoing randomized controlled critical care trials. *Crit Care* 2017; **21**: 132 [PMID: 28583149 DOI: 10.1186/s13054-017-1726-x]

24 **Krag M**, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, McArthur C, Cook D, Nielsen N, Pelosi P, Keus F, Guttormsen AB, Moller AD, Møller MH; SUP-ICU co-authors. Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients. *Intensive Care Med* 2015; **41**: 833-845 [PMID: 25860444 DOI: 10.1007/s00134-015-3725-1]

25 **Toews I**, George AT, Peter JV, Kirubakaran R, Fontes LES, Ezekiel JPB, Meerpohl JJ. Interventions for preventing upper gastrointestinal bleeding in people admitted to intensive care units. *Cochrane Database Syst Rev* 2018; **6**: CD008687 [PMID: 29862492 DOI: 10.1002/14651858.CD008687.pub2]

26 **Alhazzani W**, Alshamsi F, Belley-Cote E, Heels-Ansdell D, Brignardello-Petersen R, Alquraini M, Perner A, Møller MH, Krag M, Almenawer S, Rochwerg B, Dionne J, Jaeschke R, Alshahrani M, Deane A, Perri D, Thebane L, Al-Omari A, Finfer S, Cook D, Guyatt G. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. *Intensive Care Med* 2018; **44**: 1-11 [PMID: 29199388 DOI: 10.1007/s00134-017-5005-8]

27 **López-Herce J**, Dorao P, Elola P, Delgado MA, Ruza F, Madero R. Frequency and prophylaxis of upper gastrointestinal hemorrhage in critically ill children: a prospective study comparing the efficacy of almagate, ranitidine, and sucralfate. The Gastrointestinal Hemorrhage Study Group. *Crit Care Med* 1992; **20**: 1082-1089 [PMID: 1643886 DOI: 10.1097/00003246-199208000-00003]

28 **Kaushal** **S**, Midha V, Sood A, Chopra SC, Gupta C. A comparative study of the effects of famotidine and sucralfate in prevention of upper gastrointestinal bleeding in patients of head injury. *Indian J Pharmacol* 2000; **32**: 246–249

29 **Sasieni PD**, Wald NJ. Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies? *Circulation* 2017; **135**: 1985-1987 [PMID: 28533316 DOI: 10.1161/CIRCULATIONAHA.116.023359]

30 **Huang HB**, Jiang W, Wang CY, Qin HY, Du B. Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis. *Crit Care* 2018; **22**: 20 [PMID: 29374489 DOI: 10.1186/s13054-017-1937-1]

**P-Reviewer:** Khuroo MS, Nakajima N **S-Editor:** Wang JL **L-Editor: E-Editor:**

**Specialty type:** Medicine, research and experimental

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0